Chung-Chieh Yu1,2,3, Chih-Yu Huang1,2,3, Chung-Ching Hua1,2,3, Huang-Pin Wu4,5,6. 1. Division of Pulmonary, Critical Care, and Sleep Medicine, Chang Gung Memorial Hospital, Keelung, Taiwan. 2. Department of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan. 3. Department of Respiratory Therapy, Chang Gung Memorial Hospital, Keelung, Taiwan. 4. Division of Pulmonary, Critical Care, and Sleep Medicine, Chang Gung Memorial Hospital, Keelung, Taiwan. whanpyng@cgmh.org.tw. 5. Department of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan. whanpyng@cgmh.org.tw. 6. Department of Respiratory Therapy, Chang Gung Memorial Hospital, Keelung, Taiwan. whanpyng@cgmh.org.tw.
Abstract
PURPOSE: Continuous positive airway pressure (CPAP) is a standard treatment for obstructive sleep apnea (OSA). However, CPAP has limitations. High-flow nasal cannula (HFNC) is already in use for various types of respiratory diseases. As HFNC generates positive airway pressure, it may be a potential candidate for OSA treatment. This prospective study compared the therapeutic effects of HFNC to CPAP in patients with OSA. METHODS: Patients whose apnea-hypopnea index (AHI) was > 5 events/h were enrolled in this study. All participants were randomly divided into two groups. The first group underwent CPAP the first night and HFNC the second night. Conversely, the second group received HFNC the first night and CPAP the second night. Their respiratory events and sleep quality were compared using baseline polysomnography, CPAP, and HFNC. RESULTS: In total, 28 participants completed this study. Median [interquartile range] AHI (35.0 [20.0-48.6] vs. 10.8 [5.5-20.6] events/h; p < 0.001) was significantly improved by the HFNC. However, sleep quality was not improved. When CPAP was compared directly with HFNC, CPAP demonstrated a more favorable effect for respiratory events (AHI 5.0 [2.0-7.0] vs. 10.8 [5.5-20.6] events/h; p < 0.001) and sleep efficiency (88.1 [79.9-92.5] vs. 77.9 [69.2-86.6] %; p = 0.001). CONCLUSION: The efficacy of CPAP was superior to HFNC for both respiratory events and sleep quality. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03843372; URL: www. CLINICALTRIALS: gov ; Date of registration: November 2, 2019.
PURPOSE: Continuous positive airway pressure (CPAP) is a standard treatment for obstructive sleep apnea (OSA). However, CPAP has limitations. High-flow nasal cannula (HFNC) is already in use for various types of respiratory diseases. As HFNC generates positive airway pressure, it may be a potential candidate for OSA treatment. This prospective study compared the therapeutic effects of HFNC to CPAP in patients with OSA. METHODS: Patients whose apnea-hypopnea index (AHI) was > 5 events/h were enrolled in this study. All participants were randomly divided into two groups. The first group underwent CPAP the first night and HFNC the second night. Conversely, the second group received HFNC the first night and CPAP the second night. Their respiratory events and sleep quality were compared using baseline polysomnography, CPAP, and HFNC. RESULTS: In total, 28 participants completed this study. Median [interquartile range] AHI (35.0 [20.0-48.6] vs. 10.8 [5.5-20.6] events/h; p < 0.001) was significantly improved by the HFNC. However, sleep quality was not improved. When CPAP was compared directly with HFNC, CPAP demonstrated a more favorable effect for respiratory events (AHI 5.0 [2.0-7.0] vs. 10.8 [5.5-20.6] events/h; p < 0.001) and sleep efficiency (88.1 [79.9-92.5] vs. 77.9 [69.2-86.6] %; p = 0.001). CONCLUSION: The efficacy of CPAP was superior to HFNC for both respiratory events and sleep quality. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03843372; URL: www. CLINICALTRIALS: gov ; Date of registration: November 2, 2019.
Authors: E Shahar; C W Whitney; S Redline; E T Lee; A B Newman; F J Nieto; G T O'Connor; L L Boland; J E Schwartz; J M Samet Journal: Am J Respir Crit Care Med Date: 2001-01 Impact factor: 21.405
Authors: N McArdle; G Devereux; H Heidarnejad; H M Engleman; T W Mackay; N J Douglas Journal: Am J Respir Crit Care Med Date: 1999-04 Impact factor: 21.405
Authors: Chamara V Senaratna; Jennifer L Perret; Caroline J Lodge; Adrian J Lowe; Brittany E Campbell; Melanie C Matheson; Garun S Hamilton; Shyamali C Dharmage Journal: Sleep Med Rev Date: 2016-07-18 Impact factor: 11.609
Authors: Brian M McGinley; Susheel P Patil; Jason P Kirkness; Philip L Smith; Alan R Schwartz; Hartmut Schneider Journal: Am J Respir Crit Care Med Date: 2007-03-15 Impact factor: 21.405
Authors: E Ballester; J R Badia; L Hernández; E Carrasco; J de Pablo; C Fornas; R Rodriguez-Roisin; J M Montserrat Journal: Am J Respir Crit Care Med Date: 1999-02 Impact factor: 21.405